Imugene LtdASX: IMU

Imugene Receives $2.1M R&D Tax Refund

· Issued by Imugene Ltd via ASX

Filed with ASX · · 1 page · English

Summary by 6ix AI

Imugene Ltd has announced the receipt of a research and development tax refund for the financial year, which will support ongoing clinical activities. This funding will assist in patient recruitment for a specific phase of their clinical study involving a CAR T therapy.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement Imugene Receives $2.1m R&D Tax Refund Sydney, Australia, 16 November 2026: Imugene Limited (ASX: IMU), a clinical-stage immuno- oncology company, is pleased to announce it has received its research and development (R&D) tax refund for the 2026 financial year, totaling A$2,145,157....

Imugene Ltd on 6ix

Story so far

Earlier from Imugene

All Imugene news releases